Exome testing has proven to be a powerful tool in identifying a diagnosis in people with congenital anomalies, intellectual disability, developmental delay, epilepsy, autism, and other neurodevelopmental disorders. Laboratories continue to explore test enhancements that can improve exome testing. Recently, Ambry Genetics launched ExomeReveal, an exome test that adds the power of RNA analysis to exome testing, increasing the diagnostic yield and lowering the rate of variants of uncertain significance (VUS).
Learning Objectives
- Explain the key features, benefits, and underlying technology of ExomeReveal.
- Define how the addition of RNA analysis to exome testing provides a deeper level of information when evaluating potential splice site variants.
- Discuss future directions for RNA analysis and other supplemental technologies to enhance diagnostic yield.
*CEU credit is not available for this webinar.*